• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆固醇水平与甲状腺眼病之间的关系。

The relationship between cholesterol levels and thyroid eye disease.

作者信息

Cardo Caroline, Bernardo Santos Roberto, Pinotti Pedro Miklos Ana Beatriz, Barbosa Jaconis Sabrina, Romaldini João Hamilton, Villagelin Danilo

出版信息

Eur Thyroid J. 2025 Feb 3;14(1). doi: 10.1530/ETJ-24-0133. Print 2025 Feb 1.

DOI:10.1530/ETJ-24-0133
PMID:39819487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11825156/
Abstract

BACKGROUND

Thyroid eye disease (TED) is the most prevalent extrathyroidal manifestation of Graves' disease (GD). Emerging evidence suggests a relationship between elevated total and low-density lipoprotein (LDL) cholesterol levels and TED. This study aimed to investigate this correlation in the Brazilian population by analyzing data from two tertiary care centers.

METHODS

Data were collected from GD patients treated with methimazole between 1999 and 2021, excluding those receiving other treatments. Laboratory results and information on smoking habits, statin use and medications affecting lipid profiles during the euthyroid state were analyzed.

RESULTS

Smoking and elevated LDL cholesterol levels were significantly associated with TED activity and severity. Logistic regression revealed correlations between higher LDL cholesterol, total cholesterol and increased clinical activity score (P < 0.01, OR: 1.012, 95% CI: 1.003-1.021; P < 0.01, OR: 1.010, 95% CI: 1.002-1.018). These were also associated with more severe disease forms as defined by EUGOGO (P < 0.01, OR: 1.015, 95% CI: 1.006-1.024; P < 0.005, OR: 1.011, 95% CI: 1.004-1.019). Multiple regression confirmed that TED activity was significantly correlated with LDL cholesterol (P < 0.01) and smoking status (P < 0.01). Disease severity was associated with reduced HDL cholesterol (P < 0.05, OR: 0.973, 95% CI: 0.948-0.999), elevated LDL cholesterol (P < 0.005, OR: 1.013, 95% CI: 1.004-1.023) and active smoking (P < 0.05, OR: 2.881, 95% CI: 1.190-6.971).

CONCLUSION

Elevated LDL cholesterol may serve as a potential indicator of TED. Further research is needed to determine whether lipid-lowering interventions could reduce TED risk or improve its management.

摘要

背景

甲状腺眼病(TED)是格雷夫斯病(GD)最常见的甲状腺外表现。新出现的证据表明,总胆固醇和低密度脂蛋白(LDL)胆固醇水平升高与TED之间存在关联。本研究旨在通过分析来自两个三级医疗中心的数据,调查巴西人群中的这种相关性。

方法

收集1999年至2021年期间接受甲巯咪唑治疗的GD患者的数据,排除接受其他治疗的患者。分析实验室结果以及关于吸烟习惯、他汀类药物使用情况和甲状腺功能正常状态下影响血脂谱的药物的信息。

结果

吸烟和LDL胆固醇水平升高与TED的活动度和严重程度显著相关。逻辑回归显示,较高的LDL胆固醇、总胆固醇与临床活动评分增加之间存在相关性(P < 0.01,OR:1.012,95% CI:1.003 - 1.021;P < 0.01,OR:1.010,95% CI:1.002 - 1.018)。这些还与欧洲Graves眼病研究组(EUGOGO)定义的更严重疾病形式相关(P < 0.01,OR:1.015,95% CI:1.006 - 1.024;P < 0.005,OR:1.011,95% CI:1.004 - 1.019)。多元回归证实,TED活动度与LDL胆固醇(P < 0.01)和吸烟状态(P < 0.01)显著相关。疾病严重程度与高密度脂蛋白(HDL)胆固醇降低(P < 0.05,OR:0.973,95% CI:0.948 - 0.999)、LDL胆固醇升高(P < 0.005,OR:1.013,95% CI:1.004 - 1.023)和当前吸烟(P < 0.05,OR:2.881,95% CI:1.190 - 6.971)相关。

结论

LDL胆固醇升高可能是TED的一个潜在指标。需要进一步研究以确定降脂干预措施是否可以降低TED风险或改善其管理。

相似文献

1
The relationship between cholesterol levels and thyroid eye disease.胆固醇水平与甲状腺眼病之间的关系。
Eur Thyroid J. 2025 Feb 3;14(1). doi: 10.1530/ETJ-24-0133. Print 2025 Feb 1.
2
Interaction of MMP-9 in the active phase of Graves' disease with and without ophthalmopathy.格雷夫斯病活动期伴或不伴眼病患者 MMP-9 的相互作用。
Am J Physiol Endocrinol Metab. 2024 Oct 1;327(4):E577-E584. doi: 10.1152/ajpendo.00166.2024. Epub 2024 Sep 11.
3
Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.格雷夫斯病合并甲状腺眼病的甲状腺功能亢进症治疗
J Clin Endocrinol Metab. 2025 Mar 17;110(4):922-930. doi: 10.1210/clinem/dgaf009.
4
Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.青少年格雷夫斯病中的甲状腺相关性眼病——临床、内分泌及治疗方面
J Pediatr Endocrinol Metab. 2006 Oct;19(10):1193-206. doi: 10.1515/jpem.2006.19.10.1193.
5
Risk Factors of Thyroid Eye Disease.甲状腺眼病的危险因素。
Endocr Pract. 2021 Mar;27(3):245-253. doi: 10.1016/j.eprac.2020.11.011. Epub 2020 Dec 14.
6
Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.甲状腺眼病在 Graves 病伴和不伴眼眶病患者中的认识。
Thyroid. 2019 Apr;29(4):557-562. doi: 10.1089/thy.2018.0665. Epub 2019 Mar 22.
7
A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.一种新型甲状腺刺激免疫球蛋白生物测定法是格雷夫斯眼病活动和严重程度的功能指标。
J Clin Endocrinol Metab. 2010 May;95(5):2123-31. doi: 10.1210/jc.2009-2470. Epub 2010 Mar 17.
8
Radioiodine therapy versus antithyroid medications for Graves' disease.放射性碘治疗与抗甲状腺药物治疗Graves病的比较。
Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2.
9
Assessment of Hearing Dysfunction in Patients With Graves' Disease and Thyroid Eye Disease Without or With Teprotumumab.评估格雷夫斯病和甲状腺眼病患者在使用或未使用替普罗单抗情况下的听力功能障碍
J Clin Endocrinol Metab. 2025 Feb 18;110(3):811-819. doi: 10.1210/clinem/dgae560.
10
Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.证据表明,低密度脂蛋白胆固醇的基线水平影响格雷夫斯眼病患者对静脉用皮质类固醇的临床反应。
Front Endocrinol (Lausanne). 2020 Dec 22;11:609895. doi: 10.3389/fendo.2020.609895. eCollection 2020.

引用本文的文献

1
Preventing Thyroid Eye Disease with Statins: Evidence from a Meta-Analysis.他汀类药物预防甲状腺眼病:一项荟萃分析的证据
Cureus. 2025 May 19;17(5):e84388. doi: 10.7759/cureus.84388. eCollection 2025 May.

本文引用的文献

1
Statins and thyroid eye disease (TED): a systematic review.他汀类药物与甲状腺眼病(TED):一项系统综述。
Endocrine. 2024 Jul;85(1):11-17. doi: 10.1007/s12020-023-03680-5. Epub 2024 Jan 9.
2
Associations between Lipid Profiles and Graves' Orbitopathy can Be HLA-Dependent.血脂谱与格雷夫斯眼病之间的关联可能与 HLA 有关。
Genes (Basel). 2023 May 31;14(6):1209. doi: 10.3390/genes14061209.
3
Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.甲状腺眼病的管理:美国甲状腺协会和欧洲甲状腺协会的共识声明
Eur Thyroid J. 2022 Dec 8;11(6). doi: 10.1530/ETJ-22-0189. Print 2022 Dec 1.
4
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.了解甲状腺眼病的发病机制与有效治疗相交叉。
J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S13-S26. doi: 10.1210/clinem/dgac328.
5
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.二人转:IGF-I 和 TSH 受体在甲状腺眼病中的作用。
J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S1-S12. doi: 10.1210/clinem/dgac045.
6
The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.氧化应激在格雷夫斯眼病中的作用及抗氧化剂的治疗潜力
Biomedicines. 2021 Dec 10;9(12):1871. doi: 10.3390/biomedicines9121871.
7
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.他汀类药物治疗格雷夫斯眼病(STAGO):一项 2 期、开放标签、适应性、单中心、随机临床试验。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):733-742. doi: 10.1016/S2213-8587(21)00238-2. Epub 2021 Sep 27.
8
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.2021 年欧洲 Graves 眼病专家组(EUGOGO)Graves 眼病医学管理临床实践指南。
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
9
The change in the clinical presentation of Graves' disease: a 30 years retrospective survey in an academic Brazilian tertiary center.格雷夫斯病临床表现的变化:巴西一家学术性三级中心 30 年回顾性调查。
Arch Endocrinol Metab. 2021 May 18;64(5):514-520. doi: 10.20945/2359-3997000000265.
10
Statins: A New Hope on the Horizon of Graves Orbitopathy?他汀类药物:格雷夫斯眼眶病领域的新希望?
J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2819-e2821. doi: 10.1210/clinem/dgab184.